Study on the curative effect of SanShenHuangFeng decoction on essential thrombocythemia

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079642

Enrollment

Unknown

Registered

2024-01-08

Start date

2024-01-15

Completion date

Unknown

Last updated

2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essential thrombocythemia

Interventions

treatment group:SanShenHuangFeng decoction+aspirin

control group:aspirin

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) newly diagnosed patients meeting the diagnostic criteria of essential thrombocythemia; (2) IPSET-thrombosis predicts essential thrombocythemia in low and intermediate risk groups; (3) less than 60 years old;

Exclusion criteria

Exclusion criteria: (1) secondary thrombocytosis; (2) IPSET-thrombosis predicts essential thrombocythemia in the stratified high-risk group; (3) complicated with severe cardiovascular, cerebrovascular, liver, kidney and other organ dysfunction; (4) Other therapeutic drugs had been used.

Design outcomes

Primary

Measure	Time frame
platelet value;Degree of myelofibrosis;Proportion of bone marrow blasts;	—

Secondary

Measure	Time frame
the size of spleen;	—

Countries

China

Contacts

Public ContactWuDiJiong

The First Affiliated Hospital of Zhejiang Chinese Medical University

wudijiong@zcmu.edu.cn+86 571 8662 0325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026